Zentalis Pharmaceuticals, Inc.
ZNTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001725160
In the last 90 days, Zentalis Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 114 institutions reported holding it in 13F filings for Q2 2026, worth $228.9M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Zentalis Pharmaceuticals, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 142
- +9 vs. Q3 2024
- Shares held
- 64.4M
- −6.36M (−9.0%) vs. Q3 2024
- Total value
- $195.2M
- −$65.3M (−25.1%) vs. Q3 2024
- New holders
- 33
- 57 more added
- Sold out
- 24
- 31 more reduced
3 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZNTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 114 | $228.9M |
| Q1 2026 | 102 | $101.7M |
| Q4 2025 | 86 | $54.9M |
| Q3 2025 | 99 | $79.7M |
| Q2 2025 | 117 | $64.5M |
| Q1 2025 | 132 | $92.9M |
| Q4 2024 | 142 | $195.2M |
| Q3 2024 | 136 | $261.2M |
| Q2 2024 | 145 | $314.3M |
| Q1 2024 | 142 | $1.34B |
| Q4 2023 | 120 | $1.23B |
| Q3 2023 | 137 | $1.61B |
| Q2 2023 | 134 | $2.32B |
| Q1 2023 | 110 | $1.15B |
| Q4 2022 | 106 | $1.30B |
| Q3 2022 | 121 | $1.27B |
| Q2 2022 | 122 | $1.64B |
| Q1 2022 | 128 | $2.05B |
| Q4 2021 | 139 | $3.61B |
| Q3 2021 | 116 | $2.75B |
| Q2 2021 | 120 | $2.13B |
| Q1 2021 | 95 | $1.58B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Zentalis Pharmaceuticals, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 183,678 | $556.5K | 0.00% | +154,150+522.0% | Added |
| Walleye Capital LLC | 193,709 | $586.9K | 0.01% | +193,709 | New |
| Wealth Enhancement Advisory Services, LLC | 200,113 | $606.3K | 0.00% | +132,220+194.7% | Added |
| Bank of America Corp | 215,999 | $654.5K | 0.00% | −559,537−72.1% | Reduced |
| AQR Capital Management LLC | 223,097 | $676.0K | 0.00% | +27,615+14.1% | Added |
| Jacobs Levy Equity Management, Inc | 232,058 | $703.1K | 0.00% | +232,058 | New |
| Jane Street Group, LLC | 323,514 | $980.2K | 0.00% | +162,321+100.7% | Added |
| Connor, Clark & Lunn Investment Management Ltd. | 345,039 | $1.05M | 0.00% | +115,901+50.6% | Added |
| Boxer Capital Management, LLC | 450,000 | $1.36M | 0.12% | +450,000 | New |
| Northern Trust Corp | 484,738 | $1.47M | 0.00% | +10,513+2.2% | Added |
| 5AM Venture Management, LLC | 490,000 | $1.48M | 0.35% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 493,982 | $1.50M | 0.00% | +10,644+2.2% | Added |
| Charles Schwab Investment Management Inc | 497,362 | $1.51M | 0.00% | +91,152+22.4% | Added |
| Dimensional Fund Advisors LP | 505,006 | $1.53M | 0.00% | −638−0.1% | Reduced |
| Woodline Partners LP | 530,582 | $1.61M | 0.01% | −524,700−49.7% | Reduced |
| Renaissance Technologies LLC | 539,345 | $1.63M | 0.00% | −17,599−3.2% | Reduced |
| Two Sigma Investments, LP | 616,800 | $1.87M | 0.00% | −291,801−32.1% | Reduced |
| Nuveen Asset Management, LLC | 641,407 | $1.94M | 0.00% | +167,062+35.2% | Added |
| JPMorgan Chase & Co | 859,710 | $2.60M | 0.00% | +370,511+75.7% | Added |
| Two Sigma Advisers, LP | 889,700 | $2.70M | 0.01% | −259,700−22.6% | Reduced |
| Goldman Sachs Group Inc | 918,107 | $2.78M | 0.00% | +284,043+44.8% | Added |
| Pfizer Inc | 953,834 | $2.89M | 0.11% | +953,834 | New |
| Millennium Management LLC | 957,563 | $2.90M | 0.00% | +71,477+8.1% | Added |
| Tybourne Capital Management (HK) Ltd | 961,486 | $2.91M | 0.73% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 979,855 | $2.97M | 0.00% | −57,056−5.5% | Reduced |
| Integral Health Asset Management, LLC | 1,050,000 | $3.18M | 0.28% | +1,050,000 | New |
| Acadian Asset Management LLC | 1,067,233 | $3.23M | 0.01% | +804,017+305.5% | Added |
| MPM Oncology Impact Management LP | 1,106,851 | $3.35M | 0.48% | −358,950−24.5% | Reduced |
| Verition Fund Management LLC | 1,217,094 | $3.69M | 0.02% | −287,226−19.1% | Reduced |
| D. E. Shaw & Co., Inc. | 1,239,459 | $3.76M | 0.00% | +110,882+9.8% | Added |
| State Street Corp | 1,288,985 | $3.91M | 0.00% | +42,372+3.4% | Added |
| Geode Capital Management, LLC | 1,312,964 | $3.98M | 0.00% | +20,864+1.6% | Added |
| Primecap Management Co | 1,520,630 | $4.61M | 0.00% | +22,600+1.5% | Added |
| Almitas Capital LLC | 1,626,896 | $4.93M | 1.08% | +665,968+69.3% | Added |
| Morgan Stanley | 1,713,188 | $5.19M | 0.00% | +101,621+6.3% | Added |
| Opaleye Management Inc. | 1,767,500 | $5.36M | 0.94% | +800,500+82.8% | Added |
| Decheng Capital LLC | 2,338,095 | $7.08M | 1.52% | −770,000−24.8% | Reduced |
| Citadel Advisors LLC | 3,216,727 | $9.75M | 0.01% | +499,206+18.4% | Added |
| Vanguard Group Inc | 3,271,240 | $9.91M | 0.00% | −1,341,467−29.1% | Reduced |
| BlackRock, Inc. | 4,238,089 | $12.8M | 0.00% | −523,084−11.0% | Reduced |
| Eventide Asset Management, LLC | 4,475,054 | $13.6M | 0.25% | −4,072,842−47.6% | Reduced |
| Matrix Capital Management Company, LP | 13,959,973 | $42.3M | 1.97% | 00.0% | Unchanged |
| Boxer Capital, LLC | 0 | $0 | 0.00% | −450,000−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −107,159−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −54,459−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −33,557−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −31,448−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −25,706−100.0% | Sold out |
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −21,500−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −13,676−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −13,066−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −12,303−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −11,054−100.0% | Sold out |
| Paloma Partners Management Co | 0 | $0 | 0.00% | −10,024−100.0% | Sold out |
| Erste Asset Management GmbH | 0 | $0 | 0.00% | −9,800−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −3,100−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −2,572−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −388−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −383−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −293−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −212−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −145−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −78−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −267−100.0% | Sold out |
| Mayo Clinic | – | – | – | – | Not filed |
| Raymond James & Associates | – | – | – | – | Not filed |
| FinTrust Capital Advisors, LLC | – | – | – | – | Not filed |